1.
|
Review:
I have reviewed the
interim financial statements and interim MD&A (together, the “interim
filings”) of Lorus Therapeutics Inc. (the “issuer”) for the interim period
ended February 28, 2009.
|
2.
|
No
misrepresentations:
Based on my knowledge, having exercised reasonable diligence, the interim
filings do not contain any untrue statement of a material fact or omit to
state a material fact required to be stated or that is necessary to make a
statement not misleading in light of the circumstances under which it was
made, for the period covered by the interim
filings.
|
3.
|
Fair
presentation: Based
on my knowledge, having exercised reasonable diligence, the interim
financial statements together with the other financial information
included in the interim filings fairly present in all material respects
the financial condition, results of operations and cash flows of the
issuer, as of the date of and for the periods presented in the interim
filings.
|
4.
|
Responsibility: The issuer’s other certifying
officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (DC&P) and internal control over
financial reporting (ICFR), as those terms are defined in National
Instrument 52-109 Certification
of Disclosure in Issuers’ Annual and Interim Filings, for the
issuer.
|
5.
|
Design: Subject to the limitations, if
any described in paragraphs 5.2 and 5.3, the issuer’s other certifying
officer(s) and I have, as at the end of the period covered by the interim
filings
|
|
(a)
|
designed DC&P, or caused it to
be designed under our supervision, to provide reasonable assurance
that
|
|
(i)
|
material information relating to
the issuer is made known to us by others, particularly during the period
in which the interim filings are being
prepared;
|
|
(ii)
|
information required to be
disclosed by the issuer in its annual filings, interim filings or other
reports filed or submitted by it under securities legislation is recorded,
processed, summarized and reported within the time periods specified in
securities legislation; and
|
|
(b)
|
designed ICFR, or caused it to be
designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with the issuer’s
GAAP.
|
5.1
|
Control
framework: The
control framework the issuer’s other certifying officer(s) and I used to
design the issuer’s ICFR is Internal Control - Integrated
Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission.
|
5.2
|
ICFR
- material
weakness relating to design: The issuer has disclosed in its
interim MD&A for
each material weakness relating to design existing at the end of the
interim period
|
6.
|
Reporting
changes in ICFR: The
issuer has disclosed in its interim MD&A any change in the issuer’s
ICFR that occurred during the period beginning on December 1, 2008 and
ended on February 28, 2009 that has materially affected, or is reasonably
likely to materially affect, the issuer’s
ICFR.
|
/s/ Aiping
Young
|
Aiping Young
President and
CEO
|
1.
|
Review:
I have reviewed the
interim financial statements and interim MD&A (together, the “interim
filings”) of Lorus Therapeutics Inc. (the “issuer”) for the interim period
ended February 28, 2009.
|
2.
|
No
misrepresentations:
Based on my knowledge, having exercised reasonable diligence, the interim
filings do not contain any untrue statement of a material fact or omit to
state a material fact required to be stated or that is necessary to make a
statement not misleading in light of the circumstances under which it was
made, for the period covered by the interim
filings.
|
3.
|
Fair
presentation: Based
on my knowledge, having exercised reasonable diligence, the interim
financial statements together with the other financial information
included in the interim filings fairly present in all material respects
the financial condition, results of operations and cash flows of the
issuer, as of the date of and for the periods presented in the interim
filings.
|
4.
|
Responsibility: The issuer’s other certifying
officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (DC&P) and internal control over
financial reporting (ICFR), as those terms are defined in National
Instrument 52-109 Certification
of Disclosure in Issuers’ Annual and Interim Filings, for the
issuer.
|
5.
|
Design: Subject to the limitations, if
any described in paragraphs 5.2 and 5.3, the issuer’s other certifying
officer(s) and I have, as at the end of the period covered by the interim
filings
|
|
(a)
|
designed DC&P, or caused it to
be designed under our supervision, to provide reasonable assurance
that
|
|
(i)
|
material information relating to
the issuer is made known to us by others, particularly during the period
in which the interim filings are being
prepared;
|
|
(ii)
|
information required to be
disclosed by the issuer in its annual filings, interim filings or other
reports filed or submitted by it under securities legislation is recorded,
processed, summarized and reported within the time periods specified in
securities legislation; and
|
|
(b)
|
designed ICFR, or caused it to be
designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with the issuer’s
GAAP.
|
5.2
|
Control
framework: The
control framework the issuer’s other certifying officer(s) and I used to
design the issuer’s ICFR is Internal Control - Integrated
Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission.
|
5.2
|
ICFR
- material
weakness relating to design: The issuer has disclosed in its interim MD&A
for each material weakness relating to design existing at the end of the
interim period
|
6.
|
Reporting
changes in ICFR: The
issuer has disclosed in its interim MD&A any change in the issuer’s
ICFR that occurred during the period beginning on December 1, 2008 and
ended on February 28, 2009 that has materially affected, or is reasonably
likely to materially affect, the issuer’s
ICFR.
|
/s/ Elizabeth
Williams
|
Elizabeth
Williams
Director of Finance and Acting
CFO
|